The EUROGIN HPV and Head and Neck Cancer Forum highlights areas of active investigation in the field of HPV and head and neck cancers. It offers a review of the current epidemiologic efforts which focus on the natural history of HPV infection, risk of transmission, screening for early cancer detection, and the potential impact of prophylactic HPV vaccines in the incidence of head and neck cancer, the role of HPV in benign and head and neck disease. The event evaluates how the differing biology of HPV-HNC leads to a re-assessment of clinical staging and clinical prognostic characteristics. Given the viral etiology of these tumors, sessions address to review immune evasion mechanisms utilized by HPV and the understanding of these mechanisms, with the hope of opening the path to novel immunotherapeutic strategies to reactivate the host immune response against the virus and virally-associated cancer cells.

A dedicated debate session will focus on the controversies regarding the impact of HPV infection on oro-pharyngeal cancer, including diagnosis, management and decision making.

Sunday, December 2: 08:30 - 17:00
Monday, December 3: 08:15 - 17:45

• C. Fakhry (USA),
• A. D'Souza (USA)
  

Session 1:
SUNDAY DECEMBER 2 8.30 – 10.00

Oral presentations 1

Chair: A. Psyrri

Session 2:
SUNDAY DECEMBER 2 10.30 – 12.00

Epidemiology of oral HPV infection

Chair: A. Giuliano

• Natural history (focus upon known and unknown, how compares about cervical,   persistent infection, Vaccine)
  Dahlstrom K.
• Sex differences
  Combes J-D
• Tobacco and other risk factors
  D’Souza A.
• Sampling of oral vs. tonsil
  Mirghani H.

Session 3:
SUNDAY DECEMBER 2 13.30 – 15.00

Recurrent metastatic HPV related cancer

Chair: P. Bossi

• Epidemiologic changes: Aging population
  Windon M.
• Biomarkers for detection of recurrence
  Agrawal N.
• Molecular mechanisms below tumor response in HPV-related OPC, with a focus to locally advanced disease
  Welters M.
• Response to immunotherapy in R/M orophayngeal cancer (OPC): comparing HPV-related and non HPV-related diseases
  Mesía R.

Session 4:
SUNDAY DECEMBER 2 15.30 – 17.00

Recurrent Respiratory Papillomatosis

Chair: S. Best

Recurrent Respiratory Papilloma (RRP) is a benign disease affecting the larynx of children and adults caused by infection with low-risk HPV 6 or 11. The need for recurrent surgery and its devastating effects on voice and breathing make treating this disease a great challenge. This session highlights recent developments in the epidemiology of RRP in the era of vaccination, the psychosocial impact of the disease, modern surgical treatment options, and the ongoing search for effective immunologic therapies.

• Epidemiology, Incidence, and the Impact of Vaccination
  Friedman A.
• Quality of Life and Psychosocial Effects in Patients with RRP
  San Giorgi M.
• Office-based and Operating Room Treatment of papillomatosis
  Burns J.
• Immune Polarization in RRP
  Best S.
• Immunotherapy Trials in RRP
  Allen C.

Session 5:
MONDAY DECEMBER 3 8.15 – 9.45

Oral presentations 2

Chair: V. Mehta

Session 6:
MONDAY DECEMBER 3 9.45 – 11.15

HPV and non-oropharynx cancers

Chair: L. Mell

• Larynx and oral cavity SCC (including P16 as a biomarker for HPV in non-oropharynx cancer)
  Taberna M.
• Sinonasal cancers
  Rooper L.
• Etiologic role of HPV in non-oropharynx cancers: global perspective
  Alemany L.
• Prognostic implication of HPV in non-oropharynx cancer (p16 & hpv)
  Blanchard P.

Session 7:
MONDAY DECEMBER 3 14.15 – 15.45

Risk communication and screening for oral HPV mini-presentations and debate

Chair: A. D’souza

-How to screen?

• Incidence of oropharynx cancer and risk groups with oral HPV and Serology to screen (15-20mins)
  D’Souza A.
• Oral rinses (15-20mins)
  Giuliano A.
• What does additional/ second screen look like and how intervene with suspicious? (15-20mins)
  Fakhry C.
• When to screen? (Harms and benefits) When to test for HPV/p16 in HNSCC (15-20mins)
  Franceschi S.
• Debate (and questions) (15-30 mins
  All speakers

Session 8:
MONDAY DECEMBER 3 16.15 – 17.45

New perspectives on the clinical care of oropharyngeal cancer

Chair: C. Fakhry

• Staging and limitations of the standard of care
  Fakhry C.
• The use of surgery for de-intensification
  Zevallos J.
• De-intensification of radiotherapy
  Zumsteg Z.
• The role of traditional adverse features in HPV-positive oropharynx cancer (ECS)
  Husain Z.

Session 9:
MONDAY DECEMBER 3 17.45 – 18.15

Oral presentations 3

Chair: TBD